Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor

Histology and Histopathology

Volumn 23, Issue 5, 2008, Pages 531-538

  Surowiak, Pawel ^a,b,c   Materna, Verena ^a   Maciejczyk, Adam ^c   Pudelko, Marek ^c   Suchocki, Slawomir ^e   Kedzia, Witold ^d   Nowak Markwitz, Ewa ^d   Dumanska, Malgorzata ^b   Spaczynski, Marek ^d   Zabel, Maciej ^b,d   Dietel, Manfred ^a   Lage, Hermann ^a  

^a Charité Campus Benjamin Franklin Medical Center   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Silesian Oncological Centre   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e Voivodship Hospital   (Poland)

Author keywords

Immunohisto chemistry; Ovarian cancer; P16; Prognosis

Indexed keywords

CASPASE 9; CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; CANCER STAGING; CELL NUCLEUS; CYTOPLASM; ENZYME IMMUNOASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; OVARY; OVARY TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; CASPASE 9; CELL NUCLEUS; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 40349116235     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Armes J.E., Lourie R., de Silva M., Stamaratis G., Boyd A., Kumar B., Proce G., Hyde S., Allen D., Grant P. and Venter D.J. (2005). Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int. J. Gynecol. Pathol. 24, 363-368.
2. Cannistra S.A. (2004). Cancer of the ovary. N. Engl. J. Med. 351, 2519-2529.
3. Esteller M. (2005). Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol. 45, 629-656.
4. Fiegl H., Millinger S., Mueller-Holzner E., Marth C., Ensinger C., Berger A., Klocker H., Goebel G. and Widschwendter M. (2005). Circulating tumor-specific DNA: A marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 65, 1141-1145.
5. Fujita M., Enomoto T., Haba T., Nakashima R., Sasaki M., Yoshino K., Wada H., Buzurd G.S., Matsuzaki N., Wakasa K. and Murata Y. (1997). Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int. J. Cancer 74, 148-155.
6. Gottesman M.M. (2002). Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627.
7. Hashiguchi Y., Tsuda H., Inoue T., Nishimura S., Suzuki T. and Kawamura N. (2004). Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Hum. Pathol. 35, 165-175.
8. Holschneider C.H. and Berek J.S. (2000). Ovarian cancer: epidemiology, biology, and prognostic factors. Seminars. Surgical Oncol. 19, 3-10.
9. Katsaros D., Cho W., Singal R., Fracchioli S., Rigault de la Longrais I.A., Arisio R., Massobrio M., Smith M., Zheng W., Glass J. and Yu H. (2004). Methylation of tumor supressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol. Oncol. 94, 685-692.
10. Kommoss S., du Bois A., Ridder R., Trunk M.J., Schmidt D., Pfisterer J. and Kommoss F. the AGO-OVAR. (2007). Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Br. J. Cancer 96, 306-313.
11. Kudoh K., Ichikawa Y., Yoshida S., Hirai M., Kikuchi Y., Nagata I., Miwa M. and Ichida K. (2002). Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer. Int. J. Cancer 99, 579-582.
12. Kusume T., Tsuda H., Kawabata M., Inoue T., Umesaki N., Suzuki T. and Yamamoto K. (1999). The p16-Cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin. Cancer Res. 5, 4152-4157.
13. Makaria P.B., Saboorian M.H., Ashfag R., Toyooka K.O., Minna J.D., Gazdar A.F. and Schorge J.O. (2005). Promoter hypermetylation profile of ovarian epithelial neoplasms. Clin. Cancer Res. 11, 5365-5369.
14. Materna V., Surowiak P., Markwitz E., Spaczynski M., Drag-Zalesinska M., Zabel M. and Lage H. (2007). Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. Oncol. Rep. 17, 505-516.
15. Milde-Langosch K., Ocon E., Becker G., Loning T. (1998). p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation of mutation in endometrioid and mucinous tumors. Int. J. Cancer 79, 61-65.
16. O'Neill C.J., McBride H.A., Connolly L.E., Deavers M.T., Malpica A. and McCluggage W.G. (2007). High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumor. Histopathology 50, 773-779.
17. Ohtani N., Yamakoshi K., Takahashi A. and Hara E. (2004). The p16INK4a-RB pathway: molecular link between cellular senescence and tumor supression. J. Med. Invest. 51, 146-153.
18. Remmele W. and Stegner H.E. (1987). Recommendation for uniform definition of an immunoreactive score (IRS) for immuno-histochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8, 138-140. (in German).
19. Ryan A., Al-Jehani R.M., Mulligan K.T. and Jacobs I.J. (1998). No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis. Gynecol. Oncol. 68, 14-17.
20. Shimizu Y., Kamoi S., Amada S., Akiyama F. and Silverberg S.G. (1998). Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82, 893-901.
21. Sobin L.H. and Wittekind C. (2002). TNM classification of malignant tumors. Wiley-Liss. New York.
22. Stewart W. and Kleihues P. (2003). World cancer report. IARC Press, Lyon. pp 220-222.
23. Sui L., Dong Y., Ohno M., Goto M., Inohara T., Sugimoto K., Tai Y., Hando T. and Tokuda M. (2000). Inverse expression of Cdk4 and p16 in epithelial ovarian tumors. Gynecol. Oncol. 79, 230-237.
24. Surowiak P., Materna V., Kaplenko I., Spaczyfski M., Dietel M., Lage H. and Zabel M. (2006). Topoisomerase 1A, HER-2/neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples. Histol. Histopathol. 21, 713-720.
25. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C. and Gwyther S.G. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205-216.